Avra Medical (OTC: AVMR) interview with Barry Cohen, CEO. Barry discusses the technology Avra is developing for fully autonomous robotic surgery. The company’s goal is to receive FDA approval and enter commercialization by 2020, with an initial focus on automated dermatological surgery procedures.
Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went wrong. Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of […]
Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went wrong. Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of […]
BLA update and major licensing initiatives in cancer and immunology VANCOUVER, Washington, Jan 08, 2019- CytoDyn Inc. (otc.qb:CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
